Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Patent metadata

Field	Value
Publication number	US-11084800-B2
Application number	US-201916555914-A
Country	US
Kind code	B2
Filing date	Aug 29, 2019
Priority date	Mar 1, 2017
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

First claim

We claim:

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Achillion Pharmaceuticals Inc

Inventors

• Wiles Jason Allan
• Phadke Avinash S
• Deshpande Milind
• Agarwal Atul
• Chen Dawei
• Gadhachanda Venkat Rao
• Hashimoto Akihiro
• Pais Godwin
• Wang Qiuping
• Wang Xiangzhu
• Barrish Joel Charles
• Greenlee William
• Eastman Kyle J

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07F9/6561

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title

• C07F9/65583 Primary

  each of the hetero rings containing nitrogen as ring hetero atom · CPC title

• C07F5/027

  Organoboranes and organoborohydrides · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title